For decades, pharmaceutical marketing in Bangladesh ran on a simple engine: hire a large field force, send medical representatives into doctors' chambers with literature and samples, sponsor a few events, and watch prescriptions grow. That engine built the industry. The companies winning now have added a second engine: compliant digital medico marketing.
The Old Playbook — and Why It's Breaking
1 · Doctors have less time than ever for MR visits
A busy Dhaka consultant sees 60–100 patients a day. The MR window has shrunk to two minutes — when ten companies fight for those minutes, the message that wins is the one the doctor already knows from elsewhere.
2 · The doctor generation has changed
Rising prescribers check interactions on apps, follow international guidelines online, and attend webinars. A brand that exists only in printed literature does not exist in their information world.
3 · Regulation has tightened the old tactics
The revised DGDA CPMP and the Drugs and Cosmetics Act 2023 have narrowed gift-led and inducement-led promotion. Yesterday's differentiators are today's compliance risks.
4 · Everyone's conventional marketing looks the same
Same MR model, same literature format, same sponsorships — conventional marketing has become a cost of entry, not an advantage.
5 · The patient has entered the conversation
Patients Google symptoms, watch Bengali health videos, and arrive at chambers with opinions. Conventional pharma marketing has no channel to this audience at all.
What "Enough" Looks Like in 2026: The Hybrid Engine
The answer is not firing the field force — it is multiplying it. Leading brands run every channel through one compliance gate and toward one destination: the prescriber.
The Hybrid Prescription Engine
Field force and digital channels converge through a DGDA compliance gate before reaching the doctor — while unbranded awareness shapes patient demand from below.
Digital detailing & e-content for MRs
Tablet-based interactive presentations, short clinical videos, and follow-up content sent after visits — so the two-minute chamber visit becomes a continuing conversation.
Doctor-facing digital platforms
Webinars with KOLs, digital CME, therapy-area newsletters, and closed professional communities that deliver scientific value doctors actually want. Familiarity is built before the MR knocks.
Unbranded disease awareness
Compliant public education on diabetes, hypertension, dengue, and antimicrobial resistance — growing the category and associating the company with credibility rather than claims.
Data-driven targeting
Field force hours are the most expensive asset in pharma marketing. Segmenting doctors by specialty, prescription behavior, and engagement decides where those hours earn the most.
The cost of standing still: prescription share lost to digitally-active competitors rarely comes back cheaply — habits form, formularies settle, familiarity compounds. Meanwhile field forces get more expensive every year while per-visit impact declines. Conventional-only marketing is the strategy of paying more each year for less.
Measuring a hybrid engine without fooling yourself
The hardest part of adding digital to a pharma marketing mix is not compliance and it is not content. It is measurement. Field activity has a yardstick everyone in the building already understands — calls made, coverage, frequency, and a call report at the end of the day. Digital arrives instead with a dashboard full of numbers that look like progress and, taken on their own, say almost nothing about prescriptions.
Numbers that describe attention, not intent
Webinar registrations, video views, newsletter open rates and follower counts all measure the same thing: that something reached a screen. They are worth tracking as a health check on distribution, and they are close to worthless as a measure of commercial effect. A therapy-area newsletter with a high open rate and no read-through to anything a prescriber would act on is a well-delivered piece of nothing. Report these numbers, by all means, but report them as plumbing, not as results.
Numbers worth putting in front of a brand manager
The useful questions are comparative and segment-level. Among the prescribers your field force already calls on, which ones also engage with the scientific content — and does the MR find those calls easier? Which therapy-area topics pull registrations from the specialists you actually want, rather than from a general audience? Where a doctor attends a webinar and then receives a visit, does the visit cover more ground? None of these are single numbers. All of them are answerable if engagement is recorded against the prescriber rather than against the channel.
The unit of measurement is the doctor, not the platform
This is the structural decision that determines whether any of the above is possible. If webinar attendance lives in one system, newsletter engagement in another, and call reports in a third, you will end up comparing channel totals — which is exactly the comparison that tells you nothing, because no doctor experiences your brand one channel at a time. Reporting engagement per prescriber is not a reporting refinement; it is the thing that makes a hybrid engine legible at all.
Expect this to take a cycle or two to settle. The first quarter of digital data is mostly a lesson in what you failed to instrument. That is normal, and it is a much better position than the alternative — spending a year producing scientific content with no way to tell which of it earned attention from the right prescribers. If the difference between this and a conventional consumer campaign is still not obvious, our breakdown of medico marketing versus regular marketing covers why the two disciplines measure success so differently, and our medico marketing practice page sets out how we structure the work.
Frequently Asked Questions
Does digital marketing replace medical representatives?
No. It multiplies them. Digital builds familiarity and continues the conversation; the MR closes the relationship. Brands running both report better call quality, not fewer calls.
Is digital pharma marketing legal in Bangladesh?
Yes, within limits: prescription products can be promoted to healthcare professionals (not the public), claims must be substantiated, and public-facing work must remain unbranded disease education. This is exactly why specialized compliance review matters.
Where should a pharma brand start?
Typically: (1) digital detailing content for the existing field force, (2) one doctor-facing scientific platform, and (3) one unbranded awareness campaign in a core therapy area — then scale what the data supports.
See where your brand is leaking prescription share
ceKapsys builds the hybrid engine for pharmaceutical brands in Bangladesh: DGDA-compliant digital detailing, doctor engagement platforms, and awareness campaigns audited against the CPMP before launch.
Book a strategy session